Chen Wanqiu, Choi Eun-Jung, McDougall Cameron M, Su Hua
Center for Cerebrovascular Research, Department of Anesthesia and Perioperative Care, University of California, San Francisco, 1001 Potrero Avenue, Box 1363, San Francisco, CA, 94110, USA.
Transl Stroke Res. 2014 Jun;5(3):316-29. doi: 10.1007/s12975-014-0343-0. Epub 2014 Apr 12.
Patients harboring brain arteriovenous malformation (bAVM) are at life-threatening risk of rupture and intracranial hemorrhage (ICH). The pathogenesis of bAVM has not been completely understood. Current treatment options are invasive, and ≈ 20 % of patients are not offered interventional therapy because of excessive treatment risk. There are no specific medical therapies to treat bAVMs. The lack of validated animal models has been an obstacle for testing hypotheses of bAVM pathogenesis and testing new therapies. In this review, we summarize bAVM model development and bAVM pathogenesis and potential therapeutic targets that have been identified during model development.
患有脑动静脉畸形（bAVM）的患者面临破裂和颅内出血（ICH）的危及生命风险。bAVM的发病机制尚未完全明确。目前的治疗方案具有侵入性，约20%的患者因治疗风险过高而未接受介入治疗。目前尚无治疗bAVM的特异性药物疗法。缺乏经过验证的动物模型一直是检验bAVM发病机制假说和测试新疗法的障碍。在本综述中，我们总结了bAVM模型的开发、bAVM的发病机制以及在模型开发过程中确定的潜在治疗靶点。
